Syngene International Ltd
Syngene International Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Syngene expects medium to short-term growth driven by investments in new capabilities such as peptides, ADCs, and biologics facilities in Bangalore and Bayview (Page 5). FY 2026 is viewed as a transient year with a mid-single-digit revenue growth guidance and mid-20s EBITDA margin expected; PAT margins are declining but this is considered transient and driven by one-offs.
From Syngene International Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Syngene expects medium to short-term growth driven by investments in new capabilities such as peptides, ADCs, and biologics facilities in Bangalore and Bayview (Page 5).
- Research services have shown sustained growth momentum, supported by increased biotech venture capital funding, expected to accelerate growth (Page 6).
- The global Phase III clinical trial awarded to Syngene is a strategic growth opportunity, with revenue expected to grow over FY '27 and '28 as the trial progresses (Pages 5, 14, 16).
- Current growth is moderated by inventory correction in biologics manufacturing but underlying business remains robust, with a view that FY '27 and '28 could be strong growth years (Pages 7, 12, 13).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Syngene invested roughly $200 million over the last 2 years in building capacity and capability, including biologics capacities.
- For FY '26, guided capex investment is $45 million, with an additional $10 million for the Bayview facility.
- Investment focus includes new modalities such as peptides, ADCs, biologics, and commercialization scale-up.
- New peptide facility being built in Mangalore to expand clinical and commercial scale capabilities.
- Bayview (Baltimore) biologics facility to commence commercialization in H2 FY '26; recruitment and ramp-up ongoing.
- Biologics manufacturing facility in Bangalore is operational and supplying GMP clinical supplies.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Bayview facility in Baltimore is on track to commence commercialization in the second half of the fiscal year 2026, with initial batches and qualification batches planned.
- There are numerous ongoing discussions with potential clients for the Bayview facility, reflecting a positive outlook for its order book and ramp-up.
- The Unit 3 biologics facility in Bangalore, operational since May 2025, has started supplying GMP clinical batches to a U.S. biotech client and is beginning to see ramp-up in orders.
- Syngene has been awarded its first global Phase III clinical trial contract by a U.S.-based biotech, expected to generate revenue mainly in FY 2027 and 2028 as the trial progresses.
2 more points management made on order book & pipeline
Syngene International Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.0K Cr, net profit ₹148 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Syngene International Ltd's management said in earlier quarters
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY27 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- 3B Blackbio DX Ltd (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Unihealth Hospitals Ltd (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
- Indegene (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…
- Dr Lal Pathlabs Ltd (Q2 FY26)
Sustained 11%-12% revenue growth without price hikes is planned, driven by increased patient volume and revenue per patient. Key concall takeaways from Dr Lal…
Frequently Asked Questions
What were Syngene International Ltd Q2 FY26 results?
Syngene expects medium to short-term growth driven by investments in new capabilities such as peptides, ADCs, and biologics facilities in Bangalore and Bayview (Page 5). FY 2026 is viewed as a transient year with a mid-single-digit revenue growth guidance and mid-20s EBITDA margin expected; PAT margins are declining but this is considered transient and driven by one-offs.
What is Syngene International Ltd share price analysis?
Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 55.5 with a market cap of ₹16,427 Cr. Investors should review the full earnings analysis for detailed insights.
Is Syngene International Ltd planning capital expenditure?
Syngene invested roughly $200 million over the last 2 years in building capacity and capability, including biologics capacities.
Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.